Open AccessDiagnosis and treatment of mucosa Candida spp. infections – a review article
Author(s) -
Marta Dąbrowska,
Monika Sienkiewicz,
Paweł Kwiatkowski,
Michał Dąbrowski
Publication year - 2019
Publication title -
annales universitatis mariae curie-skłodowska. sectio c, biologia
Language(s) - English
Resource type - Journals
eISSN - 2083-3563
pISSN - 0066-2232
DOI - 10.17951/c.2018.73.1.61-68
Subject(s) - nystatin , candida albicans , fluconazole , voriconazole , amphotericin b , clotrimazole , microbiology and biotechnology , candida infections , pathogen , medicine , vulvovaginal candidiasis , systemic candidiasis , immunology , antifungal , corpus albicans , biology
Candida albicans is the most common cause of fungal infections worldwide. Non-albicans Candida species play an important role in vulvovaginal candidiasis and invasive infections. Most cases of infections are endogenous. In case of patients with immune disorders this opportunistic pathogen causes both surface, systemic infections, and candidemia. Symptoms depend on the area affected. Candidiasis are treated with antimycotics; these include clotrimazole, nystatin, fluconazole, voriconazole, amphotericin B, and echinocandins. The emergence of drug resistance and the side effects of currently available antifungals are becoming a major problem in the management of Candida spp. infection.